NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that the Company will participate in two investor conferences in September:
A webcast replay will be available following the conferences and may be accessed on the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit https://minktherapeutics.com/.
Contact
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
ZURICH, March 19, 2025 /PRNewswire/ -- ArisGlobal, a leading life sciences technology company and creator…
ISM® updates its mission and offerings to serve practitioners across the global supply chain TEMPE, Ariz.,…
New AI-Powered Support Assistant Helps Blood Cancer Patients Find Answers and Resources Faster SALT LAKE…
Leveraging NVIDIA's Latest GPU Architecture to Accelerate Innovations in Ultra-Low-Dose Imaging and Enhanced Lesion Visualization…
NEW YORK, March 18, 2025 /PRNewswire/ -- DarwinHealth is proud to have been named to Fast…
PARIS and SAN FRANCISCO, March 18, 2025 /PRNewswire/ -- Moon Surgical, a French-American pioneer in surgical…